Op-Eds

Sep 29, 2016

The man behind the curtain in drug price increases

More so than most issues we deal with in Washington, health care is personal.  We all feel it when something changes in our health care system.  No one is immune, and for some, those changes mean life or death. It is very understandable, then, that fluctuation in drug prices draws so much public attention.  Lifesaving medications are not a choice for a family relying on them to protect a loved one, they are a necessity. As a pharmacist for more than 30 years, and the only pharmacist in ...

Sep 28, 2016

Mylan CEO should be ashamed of EpiPen prices

Last week the House Oversight and Government Reform Committee held a hearing on the skyrocketing price of life-saving Epinephrine Auto-Injectors, better known as the EpiPen. This hearing was especially important because EpiPens are predominantly used to keep children alive, which makes accessibility imperative. During the hearing, I and other members of the committee questioned Heather Bresch, CEO of Mylan, the pharmaceuticals company that manufactures EpiPen. Recently, Mylan has deservedly ...

Sep 19, 2016

Adopting a zero trust cyber model in government

There is no disputing the 2015 OPM data breach was a disastrous event. The implications are catastrophic and will reverberate for generations. Foreign attackers stole personally identifiable information (PII) and security clearance background investigation information of 22.1 million individuals, capturing fingerprint data of 5.6 million of those individuals. This didn’t have to happen. The arrival of sophisticated threat actors shouldn’t have come as a surprise. Federal agencies must ...